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Abstract
Background:  The Chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS) blocks the
Complement fragment C5a receptor (C5aR) and formylated peptide receptor (FPR) and is thereby a
potent inhibitor of neutrophil chemotaxis and activation of inflammatory responses. The majority of the
healthy human population has antibodies against CHIPS that have been shown to interfere with its function
in vitro. The aim of this study was to define potential epitopes for human antibodies on the CHIPS surface.
We also initiate the process to identify a mutated CHIPS molecule that is not efficiently recognized by
preformed anti-CHIPS antibodies and retains anti-inflammatory activity.
Results: In this paper, we panned peptide displaying phage libraries against a pool of CHIPS specific
affinity-purified polyclonal human IgG. The selected peptides could be divided into two groups of
sequences. The first group was the most dominant with 36 of the 48 sequenced clones represented.
Binding to human affinity-purified IgG was verified by ELISA for a selection of peptide sequences in phage
format. For further analysis, one peptide was chemically synthesized and antibodies affinity-purified on this
peptide were found to bind the CHIPS molecule as studied by ELISA and Surface Plasmon Resonance.
Furthermore, seven potential conformational epitopes responsible for antibody recognition were
identified by mapping phage selected peptide sequences on the CHIPS surface as defined in the NMR
structure of the recombinant CHIPS31–121 protein. Mapped epitopes were verified by in vitro mutational
analysis of the CHIPS molecule. Single mutations introduced in the proposed antibody epitopes were
shown to decrease antibody binding to CHIPS. The biological function in terms of C5aR signaling was
studied by flow cytometry. A few mutations were shown to affect this biological function as well as the
antibody binding.
Conclusion: Conformational epitopes recognized by human antibodies have been mapped on the CHIPS
surface and amino acid residues involved in both antibody and C5aR interaction could be defined. This
information has implications for the development of an effective anti-inflammatory agent based on a
functional CHIPS molecule with low interaction with human IgG.
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Background
Chemotaxis inhibitory protein of Staphylococcus aureus
(CHIPS) is a potent inhibitor of neutrophil chemotaxis
and activation by specifically binding and blocking the G-
protein coupled Complement fragment C5a receptor
(C5aR) and formylated peptide receptor (FPR) [1,2]. C5a
is a complement polypeptide with many functions. It
exerts pro-inflammatory effects through the C5aR and is
involved in host defense against microorganisms. The
C5a/C5aR interaction mediates immunomodulatory and
inflammatory activities such as chemotaxis, degranula-
tion, vascular permeabilisation and cytokine regulation
[3-6]. C5a plays a role in a wide variety of inflammatory
disorders like rheumatoid arthritis, inflammatory bowel
disease, immune complex disease, ischemia-reperfusion
injury and sepsis [7-13]. Since C5a is generated early in
the inflammatory cascade it is a promising target for anti-
inflammatory therapy. Several studies have demonstrated
the beneficial effects of targeting the C5aR in inflamma-
tory diseases [14-19].
The potent ability of CHIPS to inhibit activation of the
C5aR is an important asset which might be useful for
development of a potential new anti-inflammatory drug.
However, since the CHIPS gene is present in over 60% of
Staphylococcus aureus strains and S. aureus is a common
bacterium, a majority of the population encounters
CHIPS early in life. Human serum contains anti-CHIPS
antibodies that have been shown to interfere with CHIPS
function in vitro [20]. These antibodies may therefore neu-
tralize the in vivo effect of CHIPS or give rise to antibody
mediated immune reactions. As such, the potential of
CHIPS to function as an anti-inflammatory molecule is
hampered. An improved CHIPS molecule will be charac-
terized by decreased reactivity with pre-existing antibod-
ies, but preserved C5aR blocking activity. Mapping the
epitopes of human IgG on the CHIPS protein is an impor-
tant step in the understanding of how antibodies interfere
with CHIPS.
Antibody screening of phage-displayed peptide libraries is
a useful approach to identify antibody epitopes [21,22].
Previous studies showed the potential of using random
peptide phage libraries in identifying linear epitopes and
conformational epitopes for monoclonal and polyclonal
antibodies. For example, Luzzago et al. identified discon-
tinuous epitopes in human H-subunit ferritin by the use
of phage display and verified the potential epitopes by
design of variants with point mutations [23]. Rowley et al.
studied autoantibodies in primary biliary cirrhosis and
could predict the major conformational antibody epitope
using phage display and the known NMR structure of the
target protein [24]. These studies show that peptides
expressed by phage display are capable of adopting a con-
formation that mimics the epitopes.
In this paper we focus on mapping epitopes on CHIPS by
panning of phages displaying 7-mer peptides against pol-
yclonal human IgG affinity-purified on N- and C-termi-
nally truncated CHIPS. Peptides selected by phage display
could be grouped into two distinct groups based on their
sequence. These were then verified in ELISA and by the use
of a synthetic peptide. By mapping the selected peptide
sequences on the CHIPS surface using the known NMR
structure of CHIPS31–121 [25], potential conformational
epitopes for human IgG could be identified. The epitopes
were subsequently verified by mutation of key amino
acids in the CHIPS molecule and the activity of the
mutants was studied by C5aR inhibition. The mutational
analysis of the epitopes revealed amino acid residues that
are important for the interaction of CHIPS with human
antibodies. In addition, amino acids involved in the inter-
action with the C5aR were identified.
Results
Truncated CHIPS variants inhibit C5a induced cell 
activation
In order to isolate a small active CHIPS variant able to
form a functional molecule with decreased number of
antibody epitopes, we generated truncated variants of
CHIPS. Previously, we described CHIPS with N-terminal
truncation (ΔN) [25] and CHIPS with both N- and C-ter-
minal truncations (ΔN/C) [26] that showed a complete
preservation of C5aR blocking activity. Figure 1 summa-
rizes the activity of different CHIPS variants (CHIPS ΔN,
CHIPS ΔC and CHIPS ΔN/C in comparison to full-length
Truncated CHIPS variants inhibit C5a induced cell activation Figure 1
Truncated CHIPS variants inhibit C5a induced cell 
activation. Fluo-3AM labeled U937/C5aR transfectants 
were preincubated with full-length CHIPS1–121, CHIPS with 
N-terminal truncation (CHIPS ΔN), CHIPS with C-terminal 
truncation (CHIPS ΔC) and CHIPS with truncations in both 
the N- and C-terminal ends (CHIPS ΔN/C) and stimulated 
with 1 nM C5a. Results are expressed as percentage inhibi-
tion of buffer treated cells and are from a representative 
experiment.
0.001 0.01 0.1 1
0
25
50
75
100
Full-length CHIPS1-121
CHIPS ΔN
CHIPS ΔC
CHIPS ΔN/C
[CHIPS variant] (µg/ml)
R
e
l
a
t
i
v
e
 
i
n
a
c
t
i
v
a
t
i
o
n
 
(
%
)BMC Immunology 2009, 10:13 http://www.biomedcentral.com/1471-2172/10/13
Page 3 of 13
(page number not for citation purposes)
CHIPS1–121. All truncated CHIPS variants were able to
inhibit the C5a induced activation of U937/C5aR cells to
the same extent as full-length wild-type (wt) CHIPS1–121.
Hence, the smallest CHIPS variant tested, a molecule with
preserved biological activity with truncations in both the
N- and C-terminal end (resulting in a protein of 83 amino
acids) was used for further studies. This CHIPS variant has
most likely lost the ability to block activation of the FPR,
since the N-terminal amino acids of CHIPS are required
for that action [27].
Affinity-purified anti-CHIPS antibodies recognize non-
linear epitopes
In order to map antibody epitopes on CHIPS, affinity
purification of human anti-CHIPS IgG was initially per-
formed on the wt CHIPS1–121 protein. Pooled human IgG
(IV-IgG) was affinity-purified using a column packed with
immobilized CHIPS1–121 resin. We tested the binding of
affinity-purified anti-CHIPS1–121  antibodies to a set of
CHIPS derived 25-mer peptides spanning the complete
CHIPS1–121  sequence. As shown in Figure 2A, linear
epitopes do appear to be confined to the N-terminus of
CHIPS. To confirm the presence of conformational
epitopes, we tested the reactivity of two different affinity-
purified antibody preparations (anti-full-length CHIPS1–
121 and anti-CHIPS ΔN/C) to wt CHIPS1–121, CHIPS ΔN
and CHIPS ΔN/C. Figure 2B–D shows that both prepara-
tions of affinity isolated antibodies react with all three
CHIPS variants. There is no significant difference in reac-
tivity towards the different CHIPS variants between the
preparations. Reactivity of the different CHIPS variants
with the control antibody 2G8 (a monoclonal mouse
anti-CHIPS antibody [27]) was also comparable, indicat-
ing that all CHIPS variants coated equally well. These data
also imply that epitopes outside the N-terminus may be of
importance for antibody binding and that some of these
epitopes are conformational.
Panning experiments identified potential antibody 
recognition sequences
To obtain peptides mimicking epitopes other than the lin-
ear epitopes found in the N-terminus of CHIPS, two ran-
dom peptide phage libraries were screened for binding to
anti-CHIPS ΔN/C IgG. The starting material was a mixture
of two different libraries (PhD-7 displaying linear pep-
tides and PhD-C7C displaying cyclic peptides). After four
rounds of panning, 48 recombinant phage clones were
randomly selected and characterized by DNA sequencing.
The sequence 'MNKTWYP' occurred 12 times among the
sequenced clones and was thereby the most abundant fol-
lowed by 'MNKTFWF' which was selected five times. A
majority of the selected peptides (42 of 48) could be
divided into two different groups based on their amino
acid sequence as shown in Table 1. Amino acids that
occurred most frequently among the aligned sequences
for each group were classified as consensus residues. 36
sequences belonged to the first group and their consensus
sequence was defined as 'MNKT/Sxxx'. Six sequences with
the consensus sequence 'GKLPxxx' belonged to the second
group. Although we started out with a mixture of two dif-
ferent libraries (PhD-7 and PhD-C7C) with linear and cir-
cular peptides displayed, respectively, the selected
sequences were all originating from the PhD-7 library
with linear sequences. Six different recombinant phages
expressing representative peptide sequences were charac-
terized in ELISA for binding to human anti-CHIPS ΔN/C
IgG. These phages bound specifically to the antibodies
and not to BSA (Figure 3). We therefore conclude that the
binding of the selected phages to affinity-purified human
anti-CHIPS ΔN/C IgG is specific for the expressed peptide.
Synthetic peptides can be used to purify CHIPS specific 
antibodies
To investigate the specificity of antibodies purified on the
selected peptides, a synthetic peptide from the group 1
consensus sequence (MNKSYTI) was synthesized. As the
N-terminus of CHIPS was shown to contain linear
epitopes for human antibodies, a N-terminal peptide (aa
1–38) of CHIPS was used for comparison. The synthe-
sized peptides were designed to contain a C-terminal
cysteine residue that allowed immobilization by thiol
coupling chemistry. They were subsequently coupled to
activated Sepharose to create affinity columns, which were
used to capture peptide-specific antibodies from the
human polyclonal IgG pool (IV-IgG). Binding of the affin-
ity-purified anti-peptide antibodies to the CHIPS1–121
molecule was studied by ELISA and Surface Plasmon Res-
onance (SPR) (Figure 4). The affinity-purified anti-group
1 peptide antibodies, the anti-CHIPS ΔN/C antibodies as
well as affinity-purified anti-1–38 peptide antibodies were
found to bind to the native CHIPS1–121 protein in ELISA
and SPR. Preincubation with CHIPS1–121 abolished this
binding. Without affinity purification, the same concen-
tration of IV-IgG showed no detectable binding.
Potential antibody epitopes were identified on the CHIPS 
surface
To identify potential antibody epitopes, the consensus
sequences 'MNKT/Sxxx' and 'GKLPxxx', were manually
mapped onto the surface of CHIPS31–121 by structural
analysis. The fold of N-terminally truncated CHIPS con-
sists of an N-terminal amphipathic α-helix and a four-
stranded anti-parallel β-sheet as determined by multi-
dimensional NMR [25]. The structure of CHIPS with C-
terminal truncation is not yet determined, consequently
the available NMR structure was used for mapping of the
epitopes. More specifically, the suggested epitopes are
composed of adjacent amino acids found in the 3D struc-
ture (or amino acids with similar chemical properties to
those in the consensus sequences).
In total, seven different mapping possibilities of the two
consensus sequences were identified. These are denoted
Surface 1.1–1.6 and 2.1 (Table 2). Residue-residue dis-BMC Immunology 2009, 10:13 http://www.biomedcentral.com/1471-2172/10/13
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Affinity-purified anti-CHIPS IgG recognize non-linear epitopes Figure 2
Affinity-purified anti-CHIPS IgG recognize non-linear epitopes. Affinity-purified anti-CHIPS1–121 IgG was tested for the 
ability to bind CHIPS derived 25-mer peptides or full-length CHIPS in ELISA (A). Full-length CHIPS1–121 or CHIPS with N-termi-
nal truncation (CHIPS ΔN), or CHIPS with truncations in both the N- and C-terminal ends (CHIPS ΔN/C) were compared for 
reactivity with different human affinity-purified anti-full-length CHIPS1–121 IgG (B), anti-CHIPS ΔN/C IgG (C), and the CHIPS 
specific mouse monoclonal antibody 2G8 as control (D).
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tances between Cα, Cβ or the closest side chain atoms of
the epitope were measured to verify that the amino acids
building up the proposed epitopes were adjacent (See
Additional files: Table 1).
Surfaces 1.1–1.4 are based on the Group 1 consensus
sequence and are largely overlapping, differing only in
one or two amino acids (Figure 5). Surface 1.5 and 1.6 are
also based on the Group 1 consensus sequence, but they
are situated in a different part of the protein and are com-
posed of different amino acids. Only one mapping possi-
bility was found for the Group 2 consensus sequence. This
potential epitope (Surface 2.1) was situated on the oppo-
site side of the CHIPS molecule as compared to Surfaces
1.1–1.4.
Verification of proposed surfaces by mutational analysis
In an attempt to verify the proposed surfaces and their
relation to antibody epitopes, a mutational strategy was
applied. To produce mutants with key amino acids
altered, point mutations (one per sequence) were intro-
duced into the C-terminally truncated CHIPS sequence.
The specific amino acid substitutions were designed to
alter the suggested epitopes by substituting key amino
acids to residues with different chemical properties or
size. In addition, the specific amino acid substitutions
were also chosen in a way not to destabilize the protein.
Hence, similar amino acids have been substituted to dif-
ferent amino acid types depending on their location in the
protein. However, not all amino acids were suitable for
mutagenesis, as they were predicted to be important for
preserving the structure of CHIPS. These amino acids, R46
[25] as well as Y72, L76 and Y108 (with side-chains pro-
truding into the interior cavity of the protein), were there-
fore left unchanged.
The CHIPS mutants were characterized in a CHIPS capture
ELISA for decreased binding of human anti-CHIPS ΔN/C
IgG (Table 3) by making full titration curves of the
mutants. The cut-off value for decreased binding was set
to 90% of maximum binding of the wt C-terminally trun-
cated CHIPS binding curve. 9 out of the 17 mutants
showed a decreased reactivity with human anti-CHIPS
ΔN/C IgG and are marked in bold in Table 3. Each of the
seven mapped surfaces, defining potential conforma-
tional epitopes in CHIPS, involved one to three residues
Table 1: Selected phage peptide sequences were divided into 
two groups based on their amino acid sequences*.
Group 1 MNKT / S x x x Frequency
MNK T WY P ( 1 2 )
MNK T F WF ( 5 )
MNK T F F S ( 2 )
MNK S Y H L ( 2 )
MNK T F S A ( 1 )
MNK T F VD ( 1 )
MNK T F V P ( 1 )
MNK V Y L P ( 1 )
MNK S Y T I ( 1 )
MNK Y H NP ( 1 )
FNK S Y YG ( 3 )
YNK S F FM ( 2 )
YNK S F F P ( 1 )
FNK S WFP ( 1 )
LNK T F YY ( 1 )
VNK T YWK ( 1 )
Group 2 GKL P x x x
GKL P I AM ( 1 )
GKL P WPK ( 1 )
GKL P I P Y ( 1 )
GKL P P P I ( 1 )
GKL P K MT ( 1 )
GKL P K E S ( 1 )
* A consensus sequence for each group was determined and is shown 
in bold. The frequency of each peptide is shown in parenthesis. Selected phages bind human anti-CHIPS ΔN/C IgG in ELISA Figure 3
Selected phages bind human anti-CHIPS ΔN/C IgG in 
ELISA. Six different recombinant phages expressing repre-
sentative peptide sequences were characterized in ELISA for 
binding to human anti-CHIPS ΔN/C IgG. These phages were 
found to bind affinity-purified human anti-CHIPS ΔN/C IgG 
(A) but not BSA (B).
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that one by one were important for antibody binding. Res-
idues K100, S107 and N55 were found to be involved in
three suggested epitopes (K100 and S107: Surface 1.1–
1.3) (N55: Surface 1.1, 1.2 and 1.4). Other amino acids
found to be important for antibody binding were N68,
K69, K92, K95, Y97 and N111. K69 was represented in
both Surface 1.5 and 2.1, whilst the other residues were
only represented in one of the proposed surfaces.
New CHIPS variants can still block activation of the C5aR
To investigate whether the selected new CHIPS variants
with reduced antibody binding were still functional in
preventing C5a induced activation of the C5aR, the 9
mutants were purified and analyzed in a calcium flux
assay. Serial dilutions of the variants were preincubated
with Fluo-3AM labeled U937/C5aR cells and the cells
were stimulated with 1 nM C5a. Flow cytometry data
showed that mutants N55K, N68A, K69T, K92E and
N111K retained full C5aR blocking activity at 1 μg/ml. In
contrast, Y97K completely abolished and K95S, K100A
and S107N partially abolished the biological activity in
comparison to wt C-terminally truncated CHIPS (Figure
6). Thus, some mutations that interfere with antibody
binding are not compatible with biological function.
Structural comparisons using circular dichroism 
spectroscopy (CD)
The K95S, Y97K, K100A and S107N mutants showed
reduced C5aR blocking activity. In order to ascertain if this
reduced activity was due to mutation of C5aR contacting
residues and not major conformational changes com-
pared to the structure of the corresponding wt, CD spectra
for the new CHIPS variants were investigated. Even spec-
tra of variants with decreased biological activity showed a
significant absorption minimum at 205 nm similar to the
corresponding wt. These introduced mutations conse-
quently are unlikely to have affected the global fold of the
molecule (Figure 7).
Discussion
Antibodies often react with tertiary structures formed
through protein folding. In contrast to linear epitopes,
these epitopes are formed when remote amino acids in
the primary sequence of a protein are brought into close
proximity in the folded protein, hence they are referred to
as discontinuous or conformational epitopes. Antibody
screening of phage-displayed peptide libraries is an effi-
cient method to identify both linear and conformational
epitopes [21,22]. Epitopes have been revealed both for
Synthetic peptides can be used to purify CHIPS specific anti- bodies Figure 4
Synthetic peptides can be used to purify CHIPS spe-
cific antibodies. Binding of affinity-purified anti-CHIPS ΔN/
C IgG (a-CHIPS), anti-group 1 peptide (a-Gr 1 pep) and IV-
IgG to immobilized CHIPS1–121 were measured in ELISA (A) 
and SPR (B). Black bars represent binding of the different 
affinity-purified antibodies. White bars show binding of anti-
bodies that were pre-incubated with CHIPS1–121.
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Table 2: Suggested anti-CHIPS ΔN/C IgG epitopes.
Consensus group 1 MN K T / S x xx
Surface 1.1 N55 K100 T53 S107 Y108
Surface 1.2 N55 K100 S107 Y108
Surface 1.3 Q58 K100 S107 Y108
Surface 1.4 N55 K54 T53 Y108
Surface 1.5 N68 K69 G70 Y71 Y72
Surface 1.6 N111 K95 Y94 Y97 Y71
Consensus group 2 GK L P x xx
Surface 2.1 K69 L90 P35 K92 E67BMC Immunology 2009, 10:13 http://www.biomedcentral.com/1471-2172/10/13
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monoclonal [28,29] and polyclonal antibodies
[24,30,31]. In this study, we used two phage-displayed
random peptide libraries to map the epitopes for polyclo-
nal human anti-CHIPS ΔN/C IgG on CHIPS. Phage selec-
tion depends on many factors, for instance, arginines in
the displayed peptide sequence interfere with secretion of
the coat protein pIII and consequently clones with pep-
tides containing arginines are strongly selected against
[32]. Furthermore, the stringency and nature of the wash
steps can favor certain phages [33]. To increase the specif-
icity of selected phages for binding to CHIPS IgG, we used
competition elution with a high concentration of CHIPS
in the last round of selection.
Peptides found to be involved in human anti-CHIPS ΔN/
C IgG binding all originated from the phage library which
expressed linear peptides, and not from the library with
cyclic peptides. We speculate that linear peptides might
have been favorable in these selections since they may be
able to adopt more conformations than the more rigid
cyclic peptides. Mapping of the linear peptides obtained
from phage selections with anti-CHIPS ΔN/C IgG identi-
fied seven potential epitope surfaces, out of which six rep-
resent conformational epitopes. This is in accordance with
the result from the pepscan ELISA, where mainly peptides
spanning the N-terminal part of CHIPS were recognized
by anti-CHIPS IgG. Antibody binding to CHIPS is thus
likely to be a combination of interaction with conforma-
tional and linear epitopes.
The interaction between an antibody and its epitope is
dependent on several amino acid residues [34]. The
nature of the amino acid substituted in a mutagenesis
study can affect the ability to detect its involvement in the
investigated epitope [35]. Here, we have substituted resi-
dues of the suggested epitopes by amino acids with differ-
ent characteristics in an effort to detect the epitopes
recognized by polyclonal anti-CHIPS ΔN/C IgG. Further-
more, single mutations are likely to affect the binding of
only a fraction of all antibodies in a polyclonal prepara-
tion. Therefore, the effect of site-directed mutagenesis of a
single residue may be difficult to detect by ELISA, as was
found in this study. If the mutations mediating an effect
on antibody binding were combined in one sequence they
may have a synergistic effect to further decrease the anti-
body interaction with CHIPS.
Nevertheless, we were able to identify amino acid residues
important for antibody interaction. By mutagenesis of resi-
dues in the different proposed surfaces, we retrieved infor-
mation on which of the suggested surfaces were likely to be
true epitopes. Surface 1.2 and 1.6 are the surfaces affected
most by the mutagenesis. For surface 1.2, mutagenesis in
three out of three positions resulted in lower interaction
with the IgG. N55 in the loop between the α-helix and β1,
K100 in the β3 sheet and S107 located in the short loop
between β3 and β4 were all shown to be involved in anti-
body interaction. Surface 1.6 contains two amino acids
(K95 and Y97 in the β3 sheet) that upon mutagenesis
reduced the antibody binding to less than 50%, respec-
tively. N111, located in a well defined long loop between
the β2 and β3 strands, was also shown to contribute to anti-
body binding. Surface 1.1–1.4 are overlapping structures.
Surface 1.1, 1.3 and 1.4 were considered less likely to be
true epitopes since mutagenesis of amino acids T53 in sur-
face 1.1 and 1.4, Q58 in 1.3 as well as T53 and K54 in 1.4
Conformational antibody epitopes in the CHIPS31–121 struc- ture Figure 5
Conformational antibody epitopes in the CHIPS31–121 
structure. Surface representation of N-terminally truncated 
CHIPS (PDB code: 1XEE) with potential conformational anti-
body epitopes shown in different colors; surface 1.1 (red), 
surface 1.2 (orange), surface 1.3 (magenta), surface 1.4 (yel-
low), surface 1.5 (blue), surface 1.6 (green) and surface 2.1 
(cyan). Figures were generated by the PyMOL molecular 
graphics system [37].
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Table 3: Suggested anti-CHIPS ΔN/C IgG epitopes and amino acid substitutions that have been made to verify epitopes*.
Consensus group 1 MN K T / S x x x
Surface 1.1 N55K K100A T53G S107N Y108
mutations 86% 78% 93% 76% -
Surface 1.2 N55K K100A S107N Y108
mutations 86% 78% 76% -
Surface 1.3 Q58K K100A S107N Y108
mutations 90% 78% 76% -
Surface 1.4 N55K K54R T53G Y108
mutations 86% 90% 93% -
Surface 1.5 N68A K69T G70 Y71 Y72
mutations 80% 88% -9 6 % -
Surface 1.6 N111K K95S Y94H Y97K Y71K
mutations 78% 47% 97% 49% 96%
Consensus group 2 GK L P x x x
Surface 2.1 K69T L90E P35A K92E E67K
mutations 88% 92% 97% 85% 91%
* The suggested epitopes are denoted Surface 1.1–1.6 and 2.1.
Binding of anti-CHIPS ΔN/C IgG to CHIPS variants was determined by ELISA and is shown as % binding to anti-CHIPS ΔN/C IgG in the table. Nine 
unique CHIPS variants with a maximum binding lower than 90% of wt CHIPS were found. These are marked in bold and were selected for further 
characterizations. In some positions no substitutions were made. This is marked by -.
Inhibition of C5aR activity by CHIPS variants with C-terminal truncation Figure 6
Inhibition of C5aR activity by CHIPS variants with C-terminal truncation. Fluo-3AM labeled U937/C5aR transfect-
ants were preincubated with CHIPS variants and stimulated with C5a. Results are expressed as percentage inhibition of buffer 
treated cells.
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did not affect the binding to the IgG. Surface 1.5 was
another alternative epitope originating from the group 1
consensus sequence. This was the only linear epitope sug-
gested, but the relevance of this surface was difficult to ver-
ify, since two of the five proposed residues (G70 and Y72)
were not mutated. G70 and Y72 were considered important
for maintaining the structure and were not mutated for sta-
bility reasons. Surface 2.1 was the only mapping possibility
found for the group 2 consensus sequence. We consider
this to be a less likely epitope, since mutagenesis of its
amino acids did not reduce the antibody binding to a sim-
ilar extent as that observed for 1.2 or 1.6.
During the mutational analysis for verification of anti-
body epitopes, amino acids involved in the interaction
with the C5aR were also identified. The β3 sheet is com-
prised of amino acids Y94-K100 and is most likely critical
for binding to the C5aR since we show that substitutions
K95S, Y97K and K100A as well as S107N affect the C5aR
inhibiting activity of CHIPS, while leaving the CHIPS
structure intact. These data confirm previous findings
where the substitution K95A was implicated in C5aR
blocking activity [25]. Some of the amino acid residues
found to be important for the antibody interaction are
therefore also most likely important for the receptor bind-
ing properties of CHIPS. This corroborates data from
Wright et al. who recently showed that CHIPS-specific
antibodies from human serum could inhibit the binding
and activity of CHIPS to the C5aR [20].
The data about which amino acids are involved in C5aR
binding is a finding that may be utilized in the design of
an optimal CHIPS molecule that requires retained C5aR
binding and blocking in addition to minimal binding of
human antibodies. Our study suggests residues that must
be left untouched or substituted in a more conservative
manner. For certain applications, there may also be other
aspects to consider, such as analysis of the presence of T-
cell epitopes. Such a process can be added in future stud-
ies when designing new CHIPS variants.
Conclusion
In conclusion, selection of peptide displaying phage
libraries using a pool of CHIPS specific polyclonal human
IgG resulted in the identification of peptide sequences
that were mapped onto the CHIPS surface to form confor-
mational antibody epitopes. These were verified by muta-
tional analysis and at least two epitopes likely to be true
epitopes were characterized. Amino acids important for
C5aR binding within these epitopes were also identified
by the mutagenesis. The mapping of human antibody
epitopes on CHIPS is a step towards the development of
an improved CHIPS molecule. Such a C5aR antagonist
with low interaction with human IgG would potentially
be an effective anti-inflammatory agent.
Methods
Cloning, expression and purification of recombinant 
proteins
Full-length CHIPS1–121 and CHIPS with N-terminal trunca-
tion, composed of amino acids 31–121 (CHIPS ΔN) and
CHIPS with N- and C-terminal truncations, composed of
amino acids 31–113 (CHIPS ΔN/C) were cloned, expressed
and purified as described previously [27]. CHIPS with C-
terminal truncation (CHIPS ΔC) and variants thereof were
cloned in a modified pRSET B vector (Invitrogen, Carlsbad,
CA). As a result of cloning, this protein was 112 amino
acids long with two additional non-relevant amino acids
included in the C-terminal end of the expressed protein.
Cultivation was performed as described by Haas et al [27],
but the protein was purified from inclusion bodies. Briefly,
the CHIPS variants were purified from E. coli culture by lysis
of the bacteria in 1/10 culture volume binding buffer (8 M
urea, 20 mM Sodium Phosphate, 500 mM NaCl, pH 7.8).
After sonication and filtration, the lysate was loaded onto a
HisTrap Ni-column (GE Healthcare, Uppsala, Sweden).
The column was washed with binding buffer, pH 7.8, pH
6.0 and pH 5.6, respectively. CHIPS was eluted with bind-
ing buffer, pH 5.6 with 50 mM EDTA and fractions contain-
ing protein as measured by A280 were pooled and refolded
by dialysis against 50 mM Tris-HCl, pH 8.0. The His-tag
was removed as described [27].
Site-directed mutagenesis and expression of CHIPS 
variants in plate format
To be able to compare many mutants of truncated CHIPS,
a tag is required to capture the proteins and determine rel-
ative concentrations. However, CHIPS activity has proven
to be sensitive to the addition of His-tags in both the N-
CHIPS with C-terminal truncation and selected correspond- ing mutants have the same overall structure Figure 7
CHIPS with C-terminal truncation and selected cor-
responding mutants have the same overall structure. 
CD spectra of C-terminally truncated CHIPS and variants 
with reduced C5aR blocking activity, carrying one of the 
amino acid substitutions K95S, Y97K, K100A or S107N, 
were recorded. All CHIPS variants have a significant absorp-
tion minimum at 205 nm and are suggested to have the same 
overall structure as the corresponding wt protein.
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and C-terminus. These have to be cleaved off before func-
tional assays can be performed. Instead, we used a mAb
(2H7) recognition site located between residue 15 and 30
within the native CHIPS N-terminus that does not inter-
fere with C5aR blocking activity [27]. Therefore the muta-
tions were generated in CHIPS with C-terminal
truncation, leaving the N-terminal 30 amino acids
untouched for recognition by the 2H7 mAb in ELISA. Site-
directed mutagenesis was performed in order to introduce
point mutations into the CHIPS sequence with C-terminal
truncation. This was performed using the QuikChange II
mutagenesis kit (Stratagene, La Jolla, CA) according to the
manufacturer's recommendations. The new CHIPS vari-
ants were sequence verified and transformed into E. coli
BL-21 Star(DE3)pLysS (Invitrogen, Carlsbad, CA) for pro-
tein expression. Variants of CHIPS with C-terminal trun-
cation were expressed in LB medium containing 50 μg/ml
ampicillin and 34 μg/ml chloramphenicol in deep-well
plates. Overnight cultures were diluted 1/50 in fresh LB
containing 50 μg/ml ampicillin and cultured at 37°C for
3 hours. IPTG (Isopropyl β-D-Thiogalactoside) (final con-
centration 0.5 mM) (BDH, Poole, UK) was added to log-
phase cultures to induce protein expression followed by
cultivation for three hours. Protein was prepared from E.
coli lysates by freeze-thawing the E. coli pellet in a buffer
consisting of PBS-0.05% Tween-20, Complete EDTA-free
protease inhibitor (Roche, Basel, Switzerland), 25 U/ml
Benzonase (Sigma-Aldrich, St Louis, MO) and 1 KU/ml
rLysozyme (EMD Chemicals, Darmstadt, Germany). The
lysates were incubated for 30 min at room temperature
with shaking and centrifuged at 13,000 rpm for 15 min to
remove debris and were stored at -20°C.
Affinity purification of anti-peptide IgG and anti-CHIPS 
IgG
A peptide, comprising the phage derived sequence MNK-
SYTI, was synthesized with an additional C-terminal
spacer of three glycines and a cysteine for efficient cou-
pling. (Bio-synthesis; Lewisville TX). A 38-mer peptide
comprising the N-terminal part of CHIPS (first 37 amino
acids plus an additional cysteine (Pepscan, Lelystad, The
Netherlands) served as control. In order to couple the
peptides to a solid matrix, peptides were first reduced
using agarose linked Tris(2-Carboxyethyl) Phosphine
(TCEP) (Pierce, Rockford, IL) and subsequently mixed
with Sulfo-Link agarose beads (Pierce, Rockford, IL) in 50
mM Tris/HCl, pH 8,3 with 5 mM EDTA for 2 hours at
room temperature. Unreacted groups were blocked with
L-cysteine and beads were extensively washed with cou-
pling buffer and PBS. Small 1 ml columns were used for
affinity purification of IgG from a pooled human immu-
noglobulin preparation for intravenous use (IV-IgG)
(Sanquin, Amsterdam, The Netherlands). IgG was eluted
with 0.1 M glycine-HCl buffer pH 2.9 and neutralized
with 1 M Tris pH 8.0. Pooled fractions were dialyzed over-
night against PBS and the purified anti-peptide IgG was
stored at 4°C.
Purified CHIPS variants (full-length or CHIPS ΔN/C) were
coupled to CNBr activated sepharose 4B (Amersham Bio-
sciences, Uppsala, Sweden) and packed on a column
according to manufacturer's instructions. Affinity purifica-
tion was performed on an ΔKTA Prime system (Amersham
Biosciences) according to the manufacturer's protocol. A
total of 1 g IV-IgG (20 mg/ml) over the column. Bound
human IgG was eluted with 0.1 M Glycine pH 3.0 and the
pH neutralized with 1 M Tris, pH 8.0. Eluted fractions
containing protein were pooled and buffer was changed
to PBS on PD-10 columns (Amersham Biosciences). The
affinity-purified human anti-CHIPS IgG was stored at
4°C.
ELISA
ELISA was used for many applications throughout the
study. Nunc Maxisorb clear or white 96 well plates were
coated with the specific protein in PBS. Incubations were
carried out in a volume of 50 μl for 1 hour at RT of not
described differently, always followed by washing trice
with PBS-0.05%Tween-20. Dilution buffer for all reagents
was PBS-0.05%Tween-20 with 1% BSA or milk powder
added.
Anti-CHIPS and Pepscan ELISA
Microtiter plates were coated with CHIPS (1 μg/ml) over-
night at 4°C. Plates were blocked with PBS-0.05%Tween-
20 4% BSA and incubated with different anti-CHIPS anti-
bodies in dilution buffer with 1% BSA. Bound antibodies
were detected with goat-α-human-IgG conjugated with
peroxidase (Southern, Birmingham, USA) and TMB as
substrate. For peptide experiments, synthetic 25-mer
CHIPS derived peptides spanning the complete CHIPS1–
121 sequence were synthesized as described earlier [27].
Plates were coated with peptide (10 μM) overnight at 4°C
and ELISA was performed as described above with IgG
purified on full-length CHIPS1–121.
Binding of human anti-CHIPS ΔN/C IgG to CHIPS variants 
with C-terminal truncation
For quantification of expressed proteins, plates were
coated overnight at 4°C with 3 μg/ml monoclonal anti-
CHIPS Ab 2H7 directed against a peptide of CHIPS amino
acids 24–30 [27]. Plates were blocked in PBS-0.05%
Tween-20 with 3% milk powder, washed and incubated
with serial dilutions of lysates from CHIPS variants in
dilution buffer with 1% milk powder. Binding was
detected with 3 μg/ml polyclonal rabbit anti-CHIPS N-ter-
minal IgG (IgG produced by immunization of a rabbit
with a KLH-coupled synthetic peptide corresponding to
CHIPS N-terminal amino acids 1–14) and goat anti-rabbit
IgG-HRP (Southern Biotech, Birmingham, AL)). SuperBMC Immunology 2009, 10:13 http://www.biomedcentral.com/1471-2172/10/13
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Signal ELISA Pico Chemiluminescent Substrate (Pierce,
Rockford, IL) was added and luminescence was measured.
For detection of binding of human anti-CHIPS IgG to the
CHIPS variants, plates were coated, blocked and incu-
bated with E. coli lysates as described above. Affinity-puri-
fied human anti-CHIPS ΔN/C IgG was added and binding
was detected with goat-anti-human IgG HRP (Jackson
ImmunoResearch, West Grove, PA) and substrate as
described above.
Random peptide phage libraries and phage selection
The Ph.D.-7™ and Ph.D.-C7C™ libraries from New Eng-
land Biolabs (Ipswich, MA) were used to map the epitopes
for human IgG on the surface of the CHIPS protein.
The Ph.D.-7™ Phage Display Peptide library consists of 7-
mer random linear peptides fused with a linker sequence
(GGGS) to the N-terminus of the major coat protein pIII
of bacteriophage M13. The randomized segment of the
Ph.D.-C7C™ library is flanked by a pair of cysteine resi-
dues, which are oxidized during phage assembly to a
disulfide linkage, resulting in the displayed peptides being
presented to the target as loops [36]. Protein G coated
beads (100 μl) (Dynal, Norway) were washed three times
with 1 ml PBS-0.05% Tween-20. The washed beads were
blocked with 1 ml PBS-0.05% Tween-20, 5% BSA for 1 h
at 22°C. Beads were washed four times and resuspended
in 1 ml PBS-0.05% Tween-20. One half of the blocked
beads was used for preclearing the phage stock. Therefore,
10 μl Ph.D.-7™ and 10 μl Ph.D.-C7C™ were incubated
with blocked beads in PBS-0.05% Tween-20 and were
incubated for 30 min at 22°C under continuous agitation.
Affinity-purified human anti-CHIPS ΔN/C IgG (final con-
centration ~10 nM) was added to the precleared phages
and incubated at 22°C for 30 min. The phage/IgG suspen-
sion was added to the remaining blocked beads and incu-
bated at 22°C for 30 min. The beads were washed 10
times with PBS-0.05% Tween-20 to wash away unbound
phages. The bound phages were eluted with 0.2 M Gly-
cine, pH 2.2, 0.1% BSA for 8 min followed by neutraliza-
tion of the pH with 1 M Tris-HCl, pH 8. The eluate was
amplified and 10 μl of amplified phages was used as input
for the next selection round. To increase the specificity of
the phage selection, the bound phages in the fourth round
were eluted using competition elution with the CHIPS
protein. Bound phages were eluted by overnight incuba-
tion with 1.8 mg/ml CHIPS.
Phage titration, amplification and characterization
LB medium was inoculated with a single colony of
ER2738 E. coli and incubated at 37°C with vigorous shak-
ing until mid-log phase (OD600 ~0.5). Top agar (50% LB
agar, 50% LB medium) was melted and cooled to approx-
imately 45°C. Melted top agar (3 ml) was added to 200 μl
ER2738 E. coli and poured on top of a LB/0.5 mM IPTG/
80 μg/ml X-gal plate. 10 μl of 10-fold dilutions in LB
medium was spotted on the prepared culture plates and
incubated overnight at 37°C. The next day, plaques were
counted in order to calculate phage titers. The remaining
phage eluate was added to ER2738 E. coli culture at early
log phase (OD600 0.4–0.5) and incubated with vigorous
shaking at 37°C for 4.5 h. Cultured cells were pelleted at
4°C and phages were precipitated overnight at 4°C in
25% PEG6000 (Sigma-Aldrich, St Louis, MO) 3 M NaCl.
The precipitated phages were centrifuged for 15 min at
10,000 rpm, 4°C. The pellet containing the amplified
phages was resuspended in 200 μl PBS and titrated as
described above. After the fourth selection round no
phage amplification was performed and phages were
directly characterized by DNA sequencing.
48 different plaques from the titration plates were stabbed
with a pipette tip and used to infect 1 ml 1/100 diluted
overnight culture of ER2738 E. coli and incubated for
4.5~5 h at 37°C. Cultures were centrifuged and 500 μl of
the supernatant was precipitated with PEG6000, 3 M
NaCl for 10 min at 22°C. The samples were centrifuged
for 10 min at 13,600 rpm and the pellet was resuspended
in 100 μl 4 M NaI, 10 mM EDTA, pH 8. 250 μl 95% EtOH
was added and the samples were incubated for 10 min at
22°C to preferentially precipitate the single-stranded
phage DNA. Samples were centrifuged for 10 min at
13,600 rpm and the pellet was washed with 70% EtOH,
dried and sent for sequencing to MWG Biotech (Martin-
sried, Germany) using the PIII-96seq primer (New Eng-
land Biolabs, Ipswich, MA).
A phage ELISA was performed to test the binding specifi-
city of the selected phages for affinity-purified human
anti-CHIPS  ΔN/C IgG. Affinity-purified human anti-
CHIPS  ΔN/C IgG was coated overnight with at 4°C.
Coated and non-coated wells were blocked with PBS-
0.05% Tween-20, 5% BSA. Serial dilutions of the purified
phage stocks in dilution buffer with 1% BSA were added
and incubated for 1 h at 37°C. Detection was performed
with mouse anti-M13-mAb (1 μg/ml) (Amersham Bio-
sciences, Uppsala, Sweden) and rabbit anti-mouse IgG-
HRP (Dako A/S, Glostrup, Denmark) and OPD substrate
(O-phenylenediamine) (Sigma Aldrich, St Louis, MO).
Analysis of peptide antibody binding to CHIPS
Binding of affinity-purified antibodies and pooled human
IgG (IV-IgG) to CHIPS was studied by ELISA as described
for anti-CHIPS ΔN/C antibodies and by SPR on a Biacore
1000 instrument. 20 μl 1 mg/ml CHIPS was directly cou-
pled to an activated N-ethyl-N'(di-methylaminopro-
pyl)carbodiimide (EDC) and N-hydroxysuccinimide
(NHS) carboxymethyl dextran sensor chip (CM5). Unre-
acted groups were blocked by injection of 50 μl 1 M eth-BMC Immunology 2009, 10:13 http://www.biomedcentral.com/1471-2172/10/13
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anolamine-HCl pH 8.5. Binding assays were performed at
a constant flow rate of 5 μl/min at 25°C. Affinity-purified
antibodies and IV-IgG were diluted in HBS-EP buffer (10
mM HEPES (pH 7.4) containing 150 mM NaCl, 3 mM
EDTA and 0.005% surfactant P20). Antibodies were
allowed to interact with CHIPS for 210 s followed by a
120 s dissociation phase. Additionally, the antibodies
were preincubated with 1 mg/ml CHIPS protein to study
competition. Affinity-purified anti-peptide antibodies
were tested at a concentration of 10 μg/ml. Residual
bound antibody was removed from the sensor chip sur-
face by washing the chip for three minutes with 10 mM
glycine-HCl (pH 1.5).
Epitope mapping
The amino acid sequences of the selected phages were
aligned using the Clustal-W alignment tool http://
www.ebi.ac.uk/clustalw/. Consensus sequences were
manually mapped onto the surface of the CHIPS protein
using the CHIPS31–121 NMR structure (PDB code: 1XEE)
[25] and the PyMOL molecular graphics system [37].
Biological activity assay
The C5aR inhibiting capacity of the purified CHIPS vari-
ants with C-terminal truncation was tested by measuring
calcium release from C5a stimulated U937 cells stably
transfected with the C5aR [1]. U937 cells (human prom-
onocytic cell line) transfected with the C5aR (U937/
C5aR) were a generous gift from Dr. E. Prossnitz (Univer-
sity of New Mexico, Albuquerque, NM). Cells were grown
in 75 cm2 cell culture flasks in a 5% CO2 incubator at
37°C and were maintained in RPMI 1640 medium with L-
glutamine (Cambrex, Verviers, Belgium) and 10% FBS
(Cambrex, Verviers, Belgium). Briefly, 5 × 106/ml U937/
C5aR cells were incubated with 2 μM Fluo-3AM (Sigma
Aldrich, St Louis, MO) in RPMI 1640 medium with 0.05%
BSA for 30 min at room temperature. After washing, the
cells were preincubated with buffer or a 3-fold dilution
series of CHIPS variants (1 to 0.003 μg/ml) at room tem-
perature for 30 min. Every sample was measured on a
FACSsort flow cytometer (BD Biosciences, San José, CA)
and C5a (Sigma Aldrich, St Louis, MO) (final concentra-
tion 1 nM) was added. The cell population was gated on
forward and side scatter and results are expressed as per-
centage inhibition of calcium release as compared to cells
without addition of CHIPS.
CD spectroscopy
The structures of the purified C-terminally truncated
CHIPS variants were compared by the use of CD spectros-
copy. The experiment was carried out on a Jasco J-720
spectropolarimeter (Jasco Inc., Easton, MD) in a 2 mm
cuvette at a protein concentration of ~20 μM. Spectra were
recorded from 195 to 250 nm at 20°C, at a scan speed 50
nm/min, a time constant of 4 s, a bandwidth of 1 nm, res-
olution of 1 nm and sensitivity of 50 mdeg.
Data analysis
Data from ELISA and cellular experiments were plotted by
the use of the Prism 4 software package (GraphPad Soft-
ware Inc.). The cellular data were fitted in a nonlinear
regression model (sigmoidal dose-response curve with
variable slope).
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